Brief: SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, Potential Treatment for Type 1 Diabetes
19/10/2023 12:32
Oct 19 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS RECEIVES AUSTRALIAN APPROVAL TO
COMMENCE
PHASE 1 CLINICAL TRIAL OF SAB-142, A POTENTIAL DISEASE-MODIFYING
TREATMENT FOR TYPE 1 DIABETES
* SAB BIOTHERAPEUTICS INC - SAB BIOTHERAPEUTICS IS PURSUING
IND
FILING WITH U.S. FDA
Source text for Eikon: ID:nGNX6nclt1
Further company coverage: SABS.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies